Subscribe Become an Author Sign Up Log In
Private Company

Website

Contact us at info@biopharmatrend.com to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).

Standigm

Private

About

Standigm applies cutting-edge AI technologies to drug discovery. AI and biology experts team up to build a real-world AI model for the pharmaceutical industry. We currently focus on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson’s disease (PD), autism, fatty liver diseases (NASH) and more. We promise practical benefits on time and cost in pharmaceutical industry by eliminating some of the uncertainty in the drug discovery process.

Year Founded
2015
Geography
South Korea based
Funding
$15.19 M
Patents
1
Product type
  • Small molecules
Research focus
  • Biology research (Target identification/validation)
  • Drug Repurposing
  • Lead Discovery
  • Preclinical Development

Investing history

2019Series B11.5
2016Seed round0.25
2016Series A3.0
2015Seed round0.44

Industry Partnerships

YearPartnerFocus
2017CrystalGenomicsdiscover and develop novel drugs in the therapeutic area of cancer, rheumatoid arthritis and liver related diseases.

Posts Mentioning This Company

Biopharma Insights